

Connect with C-Path at BIO 2024: Join us on the path forward in drug development

Niklas Blomberg, PhD Executive Director nnovative Health Initiative	Annette Bakker, PhD President Children's Tumor Foundation	Klaus Romero, MD Chief Executive Officer, Chief Science Officer Critical Path Institute	Nathalie Moll, MS Director General EFPIA - European Federation of Pharmacoutical Industries and Associations	Deborah Requesens, PhD Director, JumpStart Program Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania	thr Co	eaking the Rare Disease Deadloc rough Multi-Stakeholder Ilaboration dresday, June 05, 2024
/e're partner	ring at	Susan Winck RPh, Esq CEO Reagan-Udall	ler, Klaus Romer Chief Executive Officer, Chief S	o, MD Adora No PharmD,	du, ,JD ulatory	Orphan and Rare Disease • 264 Advancing the Global Regulatory Decision-Making with Public Private Partnerships

C-Path CEO Klaus Romero will be a panelist in two sessions at the upcoming BIO 2024 Conference. In two featured sessions, discover how C-Path drives innovation and removes bottlenecks in the drug development process. Connect with us throughout the event to discuss your unique challenges, prospective partnerships, and how we can guide you forward on the path to success. In addition to our sessions, we'll have C-Path staff onsite. Partner with us on the BIO One-on-One Partnering Platform

Event website: https://convention.bio.org/

Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration

Advancing the Global Regulatory Decision-Making with Public Private Partnerships

More information: partnerships@c-path.org